Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.46 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3308451 | 1.00 | GRM5 (0.46) | GRM5NAAAALDH1A1IDH1FAAH | |
| SCHEMBL3308447 | 1.00 | GRM5 (0.46) | GRM5NAAAALDH1A1IDH1FAAH | |
| SCHEMBL18122135 | 0.91 | CACNA1G (0.43) | GRM5NAAAALDH1A1FAAH | |
| SCHEMBL1750169 | 0.90 | ALDH1A1 (0.55) | NAAAALDH1A1IDH1FAAH | |
| SCHEMBL1750168 | 0.90 | ALDH1A1 (0.55) | NAAAALDH1A1IDH1FAAH | |
| SCHEMBL4299854 | 0.89 | NAAA (0.46) | GRM5NAAAALDH1A1IDH1FAAH | |
| SCHEMBL19713409 | 0.89 | NAAA (0.46) | GRM5NAAAALDH1A1IDH1FAAH | |
| SCHEMBL4299858 | 0.89 | NAAA (0.46) | GRM5NAAAALDH1A1IDH1FAAH | |
| SCHEMBL27009026 | 0.88 | FAAH (0.49) | NAAAALDH1A1IDH1FAAH | |
| SCHEMBL27009889 | 0.88 | FAAH (0.49) | NAAAALDH1A1IDH1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723733-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190177316-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-06-13 | — | — | US | disclosed |
| WO-2019113175-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| US-8242174-B2 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2012-06-21 | — | — | US | disclosed |
| US-7807720-B2 | Hydroxamic acid derivatives of 3-phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC (US) | 2010-10-05 | — | — | US | disclosed |
| US-20080188566-A1 | Hydroxamic acid derivatives of 3-Phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning | PAN THERA BIOPHARMA,LLC | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177316-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | GRM5 4196/4885NAAA 3590/4885ALDH1A1 2870/4885 |
| US-10723733-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | GRM5 4196/4885NAAA 3590/4885ALDH1A1 2870/4885 |
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | ANTXR2, AGXT, AADAC | GRM5 3828/4885NAAA 6/4885ALDH1A1 715/4885 |
| US-20080188566-A1 | Hydroxamic acid derivatives of 3-Phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning | ANTXR2, PAOX, AGXT | GRM5 2464/4885NAAA 10/4885ALDH1A1 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.